Histologic changes in ovary, uterus, vagina, and mammary gland of mature beagle dogs treated with the SERM idoxifene

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 80, Issue 3, 2007, Pages 225-232

  Rehm, Sabine ^a   Solleveld, Henk A ^a   Portelli, Samm T ^a   Wier, Patrick J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Dogs; Endometrium; Idoxifene; Ovary; SERM; Vagina estrogenic

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANTIESTROGEN; ESTROGEN; IDOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; ENDOMETRIAL DISEASE; ESTROGEN ACTIVITY; FEMALE; FEMALE GENITAL SYSTEM; HISTOPATHOLOGY; MYOMETRIUM; NEUTROPHIL COUNT; NONHUMAN; OVARY; OVARY INSUFFICIENCY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TOXICOKINETICS; UTERUS; VAGINA; VAGINA DISCHARGE;

ANIMALS; DOGS; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; OVARY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UTERUS; VAGINA;

CANIS FAMILIARIS;

EID: 34447250023     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20119     Document Type: Review

References (26)

1. Albertazzi P, Sharma S. 2005. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 8:214-220.
2. Anrun B, Anthony M, Dunn B. 2002. The search for the ideal SERM. Expert Opin Pharmacother 3:681-691.
3. Brown AP, Morrissey RL, Crowell JA, Levine BS. 1999. Thirteen-week oral toxicity study of difluoromethylornithine in combination with tamoxifen citrate in female dogs. Cancer Chemother Pharmacol 43:479-488.
4. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC. 1991. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Can Res 51:5851-5858.
5. Cline JM, Soderqvist G, Register TC, Williams JK, Adams MR, von Schoultz B. 2001. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol 29:84-90.
6. Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Dören M, Rydh W, Rudenstam G, Granberg S. 2000. The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet 263:170-177.
7. El Etreby MF. 1979. Effect of cyproterone acetate, levornorgestrel and progesterone on adrenal glands and reproductive organs in the beagle bitch. Cell Tissue Res 200:229-243.
8. Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE. 1979. Tamoxifen. In: Goldberg ME, editor. Pharmacological and biochemical properties of drug substances, Vol. 2. Washington DC: American Pharmaceutical Association. p 355-399.
9. Hart JE. 1990. Endocrine pathology of estrogens: species differences. Pharmacol Ther 47:203-218.
10. Hendrix SL, McNeely SG. 2001. Effect of selective estrogen receptor modulators on reproductive tissues other than the endometrium. Ann NY Acad SCI 949:243-250.
11. Heywood R, Wadsworth PF. 1981. The experimental toxicology of estrogens. In: RR Chaudhury, editor. Pharmacology of estrogens. International encyclopedia of pharmacology and therapeutics, Section 106. New York: Pergamon Press. p 63-80.
12. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB. 1989. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem 32:2527-2533.
13. McCluggage WG, Desai V, Manek S. 2000. Tamoxifen-associated postmenopausal adenomyosis exhibits stromal fibrosis, glandular dilatation and epithelial metaplasias. Histopathology 37:340-346.
14. McDonnell DP, Wijayaratne, A, Chang C-Y, Norris JD. 2002. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol 90(Suppl):35F-43F.
15. Miller CP. 2002. SERMs: evolutionary chemistry, revolutionary biology. Curr Pharm Des 8:2089-2111.
16. Nelson LW, Kelly WA. 1976. Progestogen-related gross and microscopic changes in female beagles. Vet Pathol 13:143-156.
17. Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, Gowen M. 1998. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 139:5224-5234.
18. O'Regan RM, Jordan VC. 2002. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and down-regulators. Lancet Oncol 3:207-214.
19. Ravn P, Nielsen TF, Christiansen C. 2006. What can be learned from the levormeloxifene experience? Acta Obstet Gynecol 85:135-142.
20. Rehm S, Stanislaus DJ. 2007. Estrous cycle-dependent histology and review of sex steroid receptor expressions in dog reproductive tissues and mammary gland and associated hormone levels. Birth Defects Res Part B: Dev Reprod Toxicol 80:in press; doi://10.1002/bdrb.20121.
21. Schwartz E, Tornaben JA, Boxill GC. 1969. Effects of chronic oral administration of a long-acting estrogen, quinestrol, to dogs. Toxicol Appl Pharmacol 14:487-494.
22. Summary Basis of Approval, Evista, application number 020815. 1998. "Center for Drug Evaluation and Research." Rockville, MD, 205p.
23. Touraine P, Driguez P, Cartier I, Yaneva H, Kuttenn F, Mauvais-Jarvis P. 1995. Lack of induction of endometrial hyperplasia with tamoxifen. Lancet 345:245-255.
24. Tucker MJ, Adams HK, Patterson JS. 1984. Tamoxifen. In: Laurence DR, McLean AEM, Wetherall M, editors. Safety tesring of new drugs. Laboratory predictions and clinical performance. London: Academic Press. p 125-161.
25. Varras M, Polyzos D, Akrivis C. 2003. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 24: 258-268.
26. Zayed I, van Esch E, McConnell RF. 1998. Systemic and histopathologic changes in beagle dogs after chronic daily oral administration of synthetic (ethinyl estradiol) or natural (estradiol) estrogens, with special reference to the kidney and thyroid. Toxicol Pathol 26:730-741.